Ymmunobio AG Signs Patent Purchase Agreement with LeukoCom GmbH
Agreement expands the company strategy to employ the immune system in the development of cancer therapies
RIEHEN, SWITZERLAND, April 7, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM antibodies as anti-cancer treatments, today announced that it has signed a purchase agreement with LeukoCom GmbH, Essen, Germany. Under the terms of the agreement, Ymmunobio acquires the patents and intellectual property to several CEACAM antibodies, including YB-200, which is currently in preclinical development as an immune-agonistic CEACAM1 antibody for the potential treatment of melanoma and other solid tumors.
"We are excited to obtain the patent rights to the new immune-agonistic CEACAM antibodies,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. “There are potential significant advantages for the treatment of solid tumors in leveraging both the physiological and pathophysiological roles of CEACAMs. This broader mechanism is a benefit as compared to other CEACAM antibodies and novel checkpoint inhibitors currently in development.”
Ymmunobio AG has the rights to CEACAM1 antibodies YB-200, YB-300, YB-400 and one additional antibody targeting CEACAM8. It will also have the rights to all future CEACAM-related patents developed or secured by LeukoCom GmbH.
Ymmunobio AG, a preclinical stage oncology biotech company, was founded by Dr. Katrin Rupalla and is committed to developing a proprietary class of CEACAM antibodies to increase the efficiency of the adaptive and innate immune system to fight cancer. Ymmunobio’s research targets defined CEACAM receptor isoforms that play a major role in the immune response and cancer cell evolution. The company’s proprietary platform is based on the leading research of Dr. Bernhard B. Singer, University Essen/Duisburg, Germany.
Contact: Dr. Katrin Rupalla, firstname.lastname@example.org